Orbit Discovery

Orbit Discovery is a pioneering company in the field of peptide-enabled drug discovery, leveraging its unique peptide display technology to identify novel therapeutic leads. The company collaborates with both industry and academic partners to discover hits for existing and novel drug targets, aiming to establish new standards of care in the therapeutic peptide market. Orbit Discovery's core business involves developing and applying innovative drug discovery platforms that deliver functional, biologically relevant peptide therapeutic leads. These peptide leads serve as key starting points for the development of peptide, peptidomimetic, and small molecule therapeutics, as well as bioconjugates for cell targeting and cargo delivery.

The company offers high throughput screening services of chemical space, performing both affinity and functional screening. Its bead-based peptide display engine allows for faster peptide discovery by binding affinity, while its ability to display a high peptide copy number facilitates the discovery of functional peptides in primary screens. Orbit's platform is target agnostic, providing access to cell surface receptors, notably GPCRs and ion channels, and can distinguish responses from single cells using microfluidics to miniaturize library production.

Orbit Discovery operates in the biotechnology and pharmaceutical markets, serving clients ranging from academic researchers to pharmaceutical companies. The business model is service-based, generating revenue through collaborative projects and service contracts for drug discovery and development.

Keywords: peptide discovery, drug discovery, peptide display technology, therapeutic leads, high throughput screening, affinity screening, functional screening, GPCRs, ion channels, microfluidics.